Structure–Activity Relationship Studies of the Peptide Antibiotic Clovibactin
Our laboratory reported the chemical synthesis and stereochemical assignment of the recently discovered peptide antibiotic clovibactin. The current paper reports an improved, gram-scale synthesis of the amino acid building block Fmoc-(2<i>R</i>,3<i>R</i>)-3-hydroxyasparagine-OH that enables structure-activity relationship studies of clovibactin. An alanine scan reveals that residues Phe<sub>1</sub>, d-Leu<sub>2</sub>, Ser<sub>4</sub>, Leu<sub>7</sub>, and Leu<sub>8</sub> are important for antibiotic activity. The side-chain amide group of the rare d-Hyn<sub>5</sub> residue is not essential to activity and can be replaced with a methyl group with a moderate loss of activity. An acyclic clovibactin analogue reveals that the macrolactone ring is essential to antibiotic activity. The enantiomer of clovibactin is active, albeit somewhat less so than clovibactin. A conformationally constrained clovibactin analogue retains moderate antibiotic activity, while a backbone <i>N</i>-methylated analogue is almost completely inactive. X-ray crystallography of these two analogues reveals that the macrolactone ring adopts a crown-like conformation that binds anions.
Authors
- Joseph W. Ziller (ORCID: https://orcid.org/0000-0001-7404-950X)
- Adam G. Kreutzer (ORCID: https://orcid.org/0000-0002-9724-6298)
- James S. Nowick (ORCID: https://orcid.org/0000-0002-2273-1029)
- Michael J. Ferracane (ORCID: https://orcid.org/0000-0002-3007-3126)
- James H. Griffin (ORCID: https://orcid.org/0009-0004-9448-1526)
- Jackson E. H. Brunicardi (ORCID: https://orcid.org/0000-0002-3661-9476)
- Ana-Teresa Mendoza
- Jeramiah Small
Institutions
- University of Redlands (US)
- University of California, Irvine (US)
Publication Details
- Journal
- The Journal of Organic Chemistry
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1021/acs.joc.4c01414
- Citations
- 7
- Primary Topic
- Biochemical and Structural Characterization
- Type
- article
- Field-Weighted Citation Impact
- 1.64
Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases